P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL
P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL
复制标题
P704：ASCIMINIB 为患有 T315I 突变的慢性粒细胞白血病慢性期 (CML-CP) 患者 (PTS) 提供持久的分子反应：来自 I 期试验的更新疗效和安全性数据
DOI：
10.1097/01.hs9.0000845700.84142.c0
复制
发表时间：
2022
期刊：
影响因子：
6.6
通讯作者：
F. Mahon
中科院分区：
文献类型：
--
作者：
T. Hughes;Jordi Cortés;D. Réa;M. Mauro;A. Hochhaus;DW Kim;K. Sasaki;F. Lang;M. Heinrich;M. Breccia;M. Deininger;Y. Goh;J. Janssen;M. Talpaz;V. Gómez García de Soria;P. le Coutre;S. Kapoor;S. Cacciatore;F. Polydoros;N. Agrawal;F. Mahon
